Padma Kodukula, Chief Executive Officer, ScopeSys Inc.

NanoSphere: Tell us a bit about yourself—your background, journey, and what led you to where you are today. 

Padma: The journey from scientific breakthrough to company value is rarely linear, and the inflection points that matter most are not always the ones you anticipate.

The first and most critical is customer proximity. Early-stage biotech companies can fall into the trap of optimizing their technology before truly understanding the problem their customer is trying to solve. At ScopeSys, we commercialize a single-particle analytics platform for mRNA-LNP characterization — novel science, but one that only delivers company value when a formulation scientist confirms it solves a problem they could not address any other way. That validation comes from sustained, direct engagement with our customers by being in the room, having honest scientific conversations, and listening more than you speak. We stay in close contact with our target customers not simply to sell, but to understand how their workflows are evolving, what regulatory pressures they face, and where the genuine analytical gaps remain. That intelligence shapes everything from product roadmap to value proposition.

The second inflection is the transition from what has been built to what the market actually needs. This is where founding teams face their greatest challenge. Markets reward solutions, not science or elegance alone. In every start-ups I have worked in, difficult decisions have been required — which applications to prioritize, which customer segments are genuinely ready, which capabilities matter versus which are scientifically interesting but commercially premature. Adaptability in this phase is a prerequisite for survival and building company value. The ability to integrate customer feedback rapidly and redirect without losing the core value of the technology is one of the most important capabilities an early-stage team can develop.

The third inflection is demonstrated value in a customer's hands. A peer-reviewed publication establishes credibility and opens doors. But the true inflection point is when a customer runs your technology on their own samples, generates data they could not have obtained otherwise, and begins asking how to secure ongoing access — the moment technology transitions from scientifically compelling to operationally necessary. At ScopeSys, every customer engagement is treated simultaneously as a commercial opportunity and a structured learning exercise. What we learn from working with a formulation team directly informs product development, refines our positioning, and strengthens every subsequent conversation.

The common thread is the capacity to move with both rigor and speed. The window between first demonstration and meaningful scale in deep tech biotech is narrower than most anticipate. Competitive dynamics shift, regulatory expectations evolve, and customer priorities change as their programs advance. An organization that can absorb new information, decide, and execute without unnecessary delay holds a genuine structural advantage. Building a culture where scientific discipline and operational agility reinforce rather than compete with each other is among the most consequential things a founding team can do.

The science creates the possibility. The customer relationship defines the direction. And the organization's capacity to adapt determines whether that possibility brings enduring company value.